文献速递认知障碍与痴呆

家族性与散发性额颞叶痴呆脑脊液TMEM106B的临床关联

Clinical Associations of Cerebrospinal Fluid TMEM106B in Familial and Sporadic Frontotemporal Dementia.
PubMed 文献 · JAMA Neurol · 2026-01-01

该横断面研究在两个独立额颞叶痴呆队列中检测脑脊液TMEM106B,发现较低水平与更严重疾病、更低额颞叶脑体积及更快临床进展相关,且受rs1990622基因型影响,但不能区分FTLD亚型或FTLD与AD。

要点

  • 脑脊液TMEM106B较低与更严重疾病、更低额颞叶脑体积和更快进展相关。
  • 该关联独立于神经丝轻链,但TMEM106B水平受rs1990622基因型影响。
  • 脑脊液TMEM106B不能区分FTLD亚型或FTLD与AD。

核心结论

  • 脑脊液TMEM106B可检测,其水平反映散发性和遗传性FTLD及AD的疾病严重程度,但也受rs1990622基因型影响。

研究设计与样本

  • 横断面研究,纳入两个独立FTD队列,发现队列n=271,验证队列n=383,含2年随访。

主要发现

  • TMEM106B与临床疾病严重程度的关联独立于神经丝轻链。
  • 保护性G/G基因型个体的TMEM106B水平低于风险A/A基因型。

关键数值与推荐

  • 脑脊液TMEM106B不能区分FTLD亚型或FTLD与AD。

临床怎么用

  • 脑脊液TMEM106B可能支持进一步研究FTLD和其他神经退行性疾病的疾病机制和临床工具开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: TMEM106B is a frontotemporal lobar degeneration (FTLD) genetic susceptibility factor, and TMEM106B protein aggregates are a feature of aging and neurodegeneration. Whether TMEM106B protein levels are associated with clinical features is unknown. OBJECTIVE: To investigate the clinical associations of cerebrospinal fluid (CSF) TMEM106B in FTLD. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study was conducted in 2 independent frontotemporal dementia (FTD) cohorts (recruitment from April 2009 through July 2023, with analyses from January 2025 through April 2026), with a 2-year follow up. This multicenter clinical study integrated clinical, genetic, biomarker, and neuroimaging data. Individuals were recruited through the University of California, San Francisco (n = 3733), or ALLFTD (n = 2343). Participants with available CSF were included. A discovery cohort (n = 271) included participants with sporadic neuropathology-confirmed FTLD; presymptomatic or symptomatic carriers of pathogenic variants in C9orf72, GRN, or MAPT; or controls. An independent validation cohort (n = 383) included participants with clinically diagnosed sporadic FTD, Alzheimer disease (AD), and controls. EXPOSURES: CSF samples for TMEM106B quantification with aptamer proteomics (SomaScan version 3.0 [discovery cohort] and SomaScan version 4.1 [validation cohort]). MAIN OUTCOMES AND MEASURES: Parametric tests compared the primary outcome, CSF TMEM106B, by disease severity, TMEM106B rs1990622 genotype, sex, clinical syndrome, pathological diagnosis, and pathogenic variant and determined associations with brain volume. RESULTS: In the discovery (n = 271; 136 women [51%]; median [IQR] age, 59 [38-80] years) and validation (n = 383; 183 women [48%]; median [IQR] age, 64 [50-78] years) cohorts, lower CSF TMEM106B was associated with more severe disease (β, -0.15; 95% CI, -0.24 to -0.04; P = .003), lower frontotemporal brain volumes (β, 0.42; 95% CI, 0.24-0.61; P < .001), and faster clinical progression (β, -2.21; 95% CI, -3.70 to -0.72; P = .001). Associations of TMEM106B with clinical disease severity were independent of those with neurofilament light chain. TMEM106B levels were influenced by TMEM106B rs1990622 genotype, where individuals with the protective G/G genotype had lower levels than the risk A/A genotype. CSF TMEM106B levels did not differentiate between FTLD subtypes or between FTLD and AD. CONCLUSIONS AND RELEVANCE: Per the results of this cross-sectional study, TMEM106B is detectable in CSF and levels reflect disease severity in sporadic and genetic FTLD and AD, but levels are also influenced by the TMEM106B rs1990622 genotype. CSF TMEM106B could support further studies to understand the mechanisms of disease and develop clinical tools in FTLD and other neurodegenerative diseases.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Olzinski M, Downer J, Cobigo Y, et al. Clinical Associations of Cerebrospinal Fluid TMEM106B in Familial and Sporadic Frontotemporal Dementia. JAMA Neurol. 2026. PMID: 42329632. doi:10.1001/jamaneurol.2026.1927

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。